BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, April 28, 2024
See today's BioWorld MedTech
Home
» Med-tech deal values soar in Q2; M&As struggle
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Med-tech deal values soar in Q2; M&As struggle
July 25, 2023
By
Karen Carey
No Comments
It only took a couple of billion-dollar transactions in the second quarter (Q2) of 2023 to push med-tech dealmaking values above all other recent years. Despite the surge in value, the volume of deals is level with other quarters.
BioWorld MedTech
Analysis and data insight
Deals and M&A